Collegium Pharmaceutical Stock Price Target and Analyst Ratings (NASDAQ:COLL)

Analyst Price Target for COLL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$25.00

▲ +11.16% Upside Potential

This price target is based on 4 analysts offering 12 month price targets for Collegium Pharmaceutical in the last 3 months. The average price target is $25.00, with a high forecast of $34.00 and a low forecast of $8.00. The average price target represents a 11.16% upside from the last price of $22.49.

Hold

The current consensus among 4 contributing investment analysts is to hold stock in Collegium Pharmaceutical. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/14/2019

0 strong buy ratings
6 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/13/2019

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/12/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/10/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

9/8/2020

0 strong buy ratings
6 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

12/7/2020

0 strong buy ratings
6 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

2/5/2021

0 strong buy ratings
2 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

3/7/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/11/2021	HC Wainwright	Boost Price Target	Buy	$29.00 ➝ $33.00	Medium	i
12/29/2020	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy		N/A	i Rating by Serge Belanger at Needham & Company LLC
11/9/2020	HC Wainwright	Reiterated Rating	Buy	$31.00 ➝ $29.00	High	i
8/21/2020	Needham & Company LLC	Reiterated Rating	Buy	$34.00	Low	i Rating by Serge Belanger at Needham & Company LLC
8/14/2020	Needham & Company LLC	Initiated Coverage	Buy	$34.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
7/24/2020	Needham & Company LLC	Initiated Coverage	Buy	$34.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
7/15/2020	Needham & Company LLC	Reiterated Rating	Buy	$34.00	Low	i Rating by Serge Belanger at Needham & Company LLC
7/14/2020	BWS Financial	Initiated Coverage	Sell	$8.00	High	i Rating by H. Khorsand at BWS Financial
7/6/2020	Needham & Company LLC	Initiated Coverage	Buy	$36.00	High	i Rating by Serge Belanger at Needham & Company LLC
6/26/2020	Needham & Company LLC	Initiated Coverage	Buy	$36.00	High	i Rating by Serge Belanger at Needham & Company LLC
6/19/2020	Needham & Company LLC	Initiated Coverage	Buy	$36.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
6/12/2020	Needham & Company LLC	Initiated Coverage	Buy	$36.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
6/5/2020	Needham & Company LLC	Initiated Coverage	Buy	$36.00	High	i Rating by Serge Belanger at Needham & Company LLC
5/29/2020	Needham & Company LLC	Initiated Coverage	Buy	$36.00	High	i Rating by Serge Belanger at Needham & Company LLC
5/26/2020	Guggenheim	Initiated Coverage	Neutral		High	i
5/22/2020	Needham & Company LLC	Initiated Coverage	Buy	$36.00	N/A	i Rating by Serge Belanger at Needham & Company LLC
5/8/2020	Needham & Company LLC	Lower Price Target	Buy	$38.00 ➝ $36.00	High	i Rating by Serge Belanger at Needham & Company LLC
4/24/2020	Needham & Company LLC	Initiated Coverage	Buy	$38.00	Low	i Rating by Serge Belanger at Needham & Company LLC
2/28/2020	William Blair	Reiterated Rating	Buy		Medium	i Rating by Tim Lugo at William Blair
2/19/2020	Jefferies Financial Group	Initiated Coverage	Buy	$43.00	Low	i
2/12/2020	Piper Sandler	Boost Price Target	Overweight	$27.00 ➝ $35.00	High	i Rating by David Amsellem at Piper Sandler
2/7/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$24.00 ➝ $30.00	High	i
2/7/2020	Needham & Company LLC	Boost Price Target	Buy	$36.00 ➝ $38.00	High	i Rating by Serge Belanger at Needham & Company LLC
2/4/2020	Piper Sandler	Reiterated Rating	Buy	$27.00	Medium	i Rating by David Amsellem at Piper Sandler
1/21/2020	Needham & Company LLC	Reiterated Rating	Buy	$36.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
1/10/2020	William Blair	Reiterated Rating	Buy		Low	i Rating by Tim Lugo at William Blair
1/8/2020	Needham & Company LLC	Boost Price Target	Hold	$28.00 ➝ $36.00	High	i Rating by Serge Belanger at Needham & Company LLC
1/8/2020	HC Wainwright	Boost Price Target	Buy ➝ In-Line	$25.00 ➝ $29.00	High	i
1/6/2020	Needham & Company LLC	Reiterated Rating	Buy	$28.00	N/A	i Rating by Serge Belanger at Needham & Company LLC
12/30/2019	Needham & Company LLC	Reiterated Rating	Buy	$28.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
12/23/2019	Needham & Company LLC	Reiterated Rating	Buy	$28.00	Low	i Rating by Serge Belanger at Needham & Company LLC
12/13/2019	Needham & Company LLC	Reiterated Rating	Buy	$28.00	Low	i Rating by Serge Belanger at Needham & Company LLC
11/8/2019	SunTrust Banks	Boost Price Target	Buy	$22.00	High	i
11/7/2019	Jefferies Financial Group	Boost Price Target		$26.00 ➝ $36.00	High	i
10/30/2019	Needham & Company LLC	Lower Price Target	Buy	$33.00 ➝ $25.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
10/18/2019	Needham & Company LLC	Set Price Target	Buy	$33.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
10/11/2019	Needham & Company LLC	Set Price Target	Buy	$33.00	Low	i Rating by Serge Belanger at Needham & Company LLC
9/27/2019	Needham & Company LLC	Set Price Target	Buy	$33.00	Medium	i Rating by Serge Belanger at Needham & Company LLC
9/17/2019	William Blair	Reiterated Rating	Buy		Low	i Rating by Tim Lugo at William Blair
8/8/2019	Cantor Fitzgerald	Reiterated Rating	Positive ➝ Overweight	$35.00 ➝ $24.00	High	i Rating by Brandon Folkes at Cantor Fitzgerald
5/3/2019	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$23.00	Low	i Rating by O. Livnat at HC Wainwright
4/26/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Low	i Rating by Brandon Folkes at Cantor Fitzgerald
4/12/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High	i Rating by Brandon Folkes at Cantor Fitzgerald
4/12/2019	Janney Montgomery Scott	Initiated Coverage	Buy	$29.00	High	i
4/5/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Low	i Rating by Brandon Folkes at Cantor Fitzgerald
3/22/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High	i Rating by Brandon Folkes at Cantor Fitzgerald
3/19/2019	SunTrust Banks	Initiated Coverage	Hold ➝ Buy	$22.00	Medium	i
3/8/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High	i Rating by Brandon Folkes at Cantor Fitzgerald
2/22/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	Low	i Rating by Brandon Folkes at Cantor Fitzgerald
2/8/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Low	i Rating by Brandon Folkes at Cantor Fitzgerald
1/25/2019	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Medium	i Rating by Brandon Folkes at Cantor Fitzgerald
1/16/2019	Needham & Company LLC	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $33.00	Low	i
1/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	High	i Rating by Brandon Folkes at Cantor Fitzgerald
11/30/2018	Cantor Fitzgerald	Set Price Target	Buy	$35.00	Low	i Rating by Brandon Folkes at Cantor Fitzgerald
11/8/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$35.00	High	i Rating by Brandon Folkes at Cantor Fitzgerald
10/24/2018	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High	i Rating by Brandon Folkes at Cantor Fitzgerald
9/21/2018	Cantor Fitzgerald	Set Price Target	Buy	$35.00	High	i Rating by Brandon Folkes at Cantor Fitzgerald
9/17/2018	HC Wainwright	Reiterated Rating	Buy		High	i Rating by E. Arce at HC Wainwright
8/9/2018	Cantor Fitzgerald	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00	High	i Rating by J. Foresi at Cantor Fitzgerald
8/6/2018	Janney Montgomery Scott	Set Price Target	Buy	$27.00	Low	i Rating by Ken Trbovich at Janney Montgomery Scott
7/11/2018	Piper Jaffray Companies	Set Price Target	Buy	$34.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
6/20/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$40.00	Low	i Rating by J. Foresi at Cantor Fitzgerald
6/14/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		Low	i Rating by J. Foresi at Cantor Fitzgerald
6/11/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$40.00	High	i
3/8/2018	William Blair	Reiterated Rating	Outperform		High	i
3/8/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$21.00 ➝ $33.00	High	i Rating by E. Arce at HC Wainwright
2/12/2018	Jefferies Financial Group	Boost Price Target	Buy	$32.00	Low	i
2/12/2018	Piper Jaffray Companies	Set Price Target	Buy	$33.00	High	i Rating by David Amsellem at Piper Jaffray Companies
2/7/2018	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $35.00	Low	i
2/6/2018	Janney Montgomery Scott	Set Price Target	Buy ➝ Buy	$21.00 ➝ $26.00	Low	i
1/23/2018	Piper Jaffray Companies	Set Price Target	Buy	$33.00	High	i Rating by David Amsellem at Piper Jaffray Companies
12/14/2017	Piper Jaffray Companies	Set Price Target	Buy	$23.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
12/7/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$24.00	Medium	i Rating by David Amsellem at Piper Jaffray Companies
12/5/2017	Needham & Company LLC	Boost Price Target	Buy ➝ Buy	$25.00 ➝ $28.00	High	i Rating by Serge Belanger at Needham & Company LLC
12/5/2017	Jefferies Financial Group	Boost Price Target	Buy	$27.00	High	i
11/29/2017	Piper Jaffray Companies	Set Price Target	Buy	$19.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
11/17/2017	HC Wainwright	Reiterated Rating	Buy	$21.00	N/A	i Rating by E. Arce at HC Wainwright
11/8/2017	HC Wainwright	Reiterated Rating	Buy	$21.00	N/A	i Rating by E. Arce at HC Wainwright
10/6/2017	Needham & Company LLC	Reiterated Rating	Buy	$25.00	N/A	i Rating by Serge Belanger at Needham & Company LLC
10/6/2017	Jefferies Financial Group	Reiterated Rating	Buy	$15.00	N/A	i
9/21/2017	Jefferies Financial Group	Reiterated Rating	Buy	$15.00	High	i Rating by David Steinberg at Jefferies Financial Group Inc.
9/11/2017	HC Wainwright	Initiated Coverage	Buy ➝ Buy	$21.00	High	i Rating by E. Arce at HC Wainwright
9/8/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$14.00	Low	i Rating by David Amsellem at Piper Jaffray Companies
7/25/2017	Piper Jaffray Companies	Set Price Target	Buy	$14.00	Medium	i Rating by David Amsellem at Piper Jaffray Companies
6/12/2017	Janney Montgomery Scott	Reiterated Rating	Buy	$25.00	Medium	i
6/9/2017	Needham & Company LLC	Reiterated Rating	Buy	$25.00	Low	i
5/31/2017	Needham & Company LLC	Reiterated Rating	Buy	$25.00	Low	i
5/11/2017	Jefferies Financial Group	Reiterated Rating	Buy	$24.00 ➝ $22.00	Low	i Rating by David Steinberg at Jefferies Financial Group Inc.
5/11/2017	Needham & Company LLC	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00	High	i
4/19/2017	Needham & Company LLC	Reiterated Rating	Buy	$30.00 ➝ $28.00	Low	i
3/25/2017	Jefferies Financial Group	Set Price Target	Buy	$24.00	Low	i Rating by David Steinberg at Jefferies Financial Group Inc.
11/11/2016	Jefferies Financial Group	Reiterated Rating	Buy	$27.00 ➝ $24.00	N/A	i
10/12/2016	Piper Jaffray Companies	Set Price Target	Buy	$23.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
9/22/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A	i
9/14/2016	Needham & Company LLC	Reiterated Rating	Buy	$30.00	N/A	i
9/13/2016	Gabelli	Initiated Coverage	Buy	$25.00	N/A	i Rating by K. Kedra at Gabelli
8/11/2016	Piper Jaffray Companies	Set Price Target	Buy	$27.00 ➝ $23.00	N/A	i Rating by david amsellem at Piper Jaffray Companies
6/23/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$26.00 ➝ $27.00	N/A	i Rating by David Amsellem at Piper Jaffray Companies
5/26/2016	Needham & Company LLC	Reiterated Rating	Buy	$28.00 ➝ $30.00	N/A	i
5/26/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$26.00	N/A	i
3/15/2016	Janney Montgomery Scott	Initiated Coverage	Buy	$25.00	N/A	i

(Data available from 3/7/2016 forward)

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and misuse, including chewing, crushing, and injecting. The company also offers Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. In addition, it offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Today's Range

Now: $22.49

$21.36

$22.61

50 Day Range

MA: $24.14

$21.75

$26.10

52 Week Range

Now: $22.49

$13.00

$26.91

Volume

385,410 shs

Average Volume

737,721 shs

Market Capitalization

$781.66 million

P/E Ratio

45.90

Dividend Yield

N/A

Beta

1.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Collegium Pharmaceutical?

The following Wall Street sell-side analysts have issued stock ratings on Collegium Pharmaceutical in the last year: BWS Financial, Guggenheim, HC Wainwright, Needham & Company LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for COLL.

What is the current price target for Collegium Pharmaceutical?

3 Wall Street analysts have set twelve-month price targets for Collegium Pharmaceutical in the last year. Their average twelve-month price target is $25.00, suggesting a possible upside of 11.2%. Needham & Company LLC has the highest price target set, predicting COLL will reach $34.00 in the next twelve months. BWS Financial has the lowest price target set, forecasting a price of $8.00 for Collegium Pharmaceutical in the next year.
View the latest price targets for COLL.

What is the current consensus analyst rating for Collegium Pharmaceutical?

Collegium Pharmaceutical currently has 1 sell rating, 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in COLL, but not buy more shares or sell existing shares.
View the latest ratings for COLL.

What other companies compete with Collegium Pharmaceutical?

Other companies that are similar to Collegium Pharmaceutical include Alkermes, Pacira BioSciences, Viela Bio, Rocket Pharmaceuticals, Corcept Therapeutics, Taro Pharmaceutical Industries, OPKO Health, Intra-Cellular Therapies, Amicus Therapeutics, Xencor, ALX Oncology, Global Blood Therapeutics, Prelude Therapeutics, Deciphera Pharmaceuticals and CytoDyn.

How do I contact Collegium Pharmaceutical's investor relations team?

Collegium Pharmaceutical's physical mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company's listed phone number is 781-713-3699. The official website for Collegium Pharmaceutical is www.collegiumpharma.com.

NASDAQ:COLL - Collegium Pharmaceutical Stock Price Target and Predictions

Analyst Price Target for COLL

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Collegium Pharmaceutical?

What is the current price target for Collegium Pharmaceutical?

What is the current consensus analyst rating for Collegium Pharmaceutical?

What other companies compete with Collegium Pharmaceutical?

How do I contact Collegium Pharmaceutical's investor relations team?